Financial Data and Key Metrics Changes - The company reported adjusted EPS of $0.56 for Q3, up from $0.48 in the prior year, while GAAP EPS was $0.14 compared to $0.31 last year [20] - Q3 revenue reached $316.2 million, reflecting a 6% organic growth year over year and a 4% reported growth [20] - Adjusted gross margin was 71.6%, slightly down from 71.9% last year, while adjusted operating margin improved to 34.9%, up 190 basis points from the prior year [22] Business Line Data and Key Metrics Changes - The Protein Sciences segment achieved reported sales of $227.7 million, with organic revenue growth of 7% [25] - The Diagnostics and Spatial Biology segment reported sales of $89.2 million, with both reported and organic growth at 2% [26] - The GMP reagents business saw trailing twelve-month growth of over 13%, while the cell and gene therapy product line had a trailing twelve-month growth rate of over 30% [12][79] Market Data and Key Metrics Changes - North America experienced low single-digit growth, driven primarily by pharma customers, while Europe saw mid single-digit growth led by academic customers [21] - China faced a mid single-digit decline due to challenging economic conditions, but the rest of Asia increased mid-teens [21] - The academic market in the U.S. was flat, impacted by NIH funding uncertainties, while the diagnostics reagents division showed year-to-date growth in the high single digits [15][21] Company Strategy and Development Direction - The company is focused on balancing investments for future growth while driving operational efficiencies, maintaining industry-leading profitability [5] - The FDA's recent emphasis on reducing animal testing is seen as an opportunity for the company's organoid solutions, which are expected to accelerate growth [11] - The company is actively managing tariff impacts through optimization of its global footprint and supply chain adjustments [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating uncertainties related to NIH funding and tariffs, noting that past experiences suggest severe cuts to NIH funding are unlikely [28][66] - The company anticipates a temporary slowdown in growth momentum to low single digits in Q4 due to macro uncertainties [31] - Management remains optimistic about long-term growth prospects, emphasizing the alignment of their product portfolio with NIH research priorities [9][66] Other Important Information - The company returned $12.6 million in dividends and $100 million through stock buybacks during Q3, with a new share repurchase program authorized for up to $500 million [24] - The balance sheet remains strong with $140.7 million in cash and a total leverage ratio well below one times EBITDA [24] Q&A Session Summary Question: Impact of NIH funding uncertainties on guidance - Management indicated that while NIH funding uncertainties are a concern, they believe the impact on long-term growth will be immaterial, as historical trends show Congress often increases NIH budgets despite proposed cuts [66][68] Question: Clarification on pharma growth rates - Management clarified that pharma experienced double-digit growth in Q3, but they expect a step down in organic growth in Q4 due to tariff impacts and academic market slowdowns [36][38] Question: Local manufacturing footprint in China - Management confirmed that tariffs have not changed their strategy for local manufacturing in China, which is seen as beneficial for minimizing cross-border tariff impacts [51] Question: Expectations for fiscal year 2026 - Management stated that they will provide a soft guide for fiscal year 2026 in three months, anticipating more clarity on headwinds affecting end markets [42][63] Question: Biotech customer spending trends - Management noted that biotech funding is sensitive to capital markets, leading to more frugal spending, which was reflected in flat growth for biotech customers in Q3 [88]

Group 1 - Bio-Techne Corporation (TECH) is experiencing significant attention from investors due to high implied volatility in its options market, particularly the Jul 18, 2025 $80 Call option [1] - Implied volatility indicates market expectations for future stock movement, suggesting potential upcoming events that could lead to substantial price changes [2] - Currently, Bio-Techne holds a Zacks Rank 4 (Sell) in the Medical - Biomedical and Genetics industry, with no analysts increasing earnings estimates for the current quarter and one analyst revising estimates downward, resulting in a consensus estimate decrease from 52 cents to 51 cents per share [3] Group 2 - The high implied volatility surrounding Bio-Techne may indicate a developing trading opportunity, as options traders often seek to sell premium on such options to capture decay, hoping the stock does not move as much as anticipated by expiration [4]

Company Performance - Techne reported quarterly earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.51 per share, and up from $0.48 per share a year ago, representing an earnings surprise of 9.80% [1] - The company posted revenues of $316.18 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.30%, and an increase from $303.43 million year-over-year [2] - Over the last four quarters, Techne has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - Techne shares have declined approximately 33.8% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.54 on revenues of $325.78 million, and for the current fiscal year, it is $1.89 on revenues of $1.22 billion [7] - The estimate revisions trend for Techne is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Techne belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Techne's stock performance [5]

Revenue Performance - Third quarter organic revenue increased by 6% to $316.2 million, with a reported revenue increase of 4%[6] - The Protein Sciences segment reported net sales of $227.7 million, a 6% increase from $214.6 million in the prior year, with 7% organic growth[11] - The Diagnostics and Spatial Biology segment's net sales were $89.2 million, a 2% increase from $87.5 million, with organic revenue growth of 2%[12] - Total consolidated net sales for the quarter ended March 31, 2025, were $316,181,000, an increase of 4.6% from $303,428,000 in the same quarter of 2024[29] - Protein Sciences segment revenue for the quarter was $227,687,000, an increase from $214,589,000 in the same quarter of 2024[40] - Diagnostics and Spatial Biology segment revenue for the quarter was $89,231,000, slightly up from $87,511,000 in the same quarter of 2024[40] Earnings and Profitability - GAAP earnings per share (EPS) was $0.14, down from $0.31 in the same quarter last year, while adjusted EPS rose to $0.56 from $0.48[6] - Adjusted operating margin improved to 34.9%, an increase of 190 basis points compared to the prior year period[4] - GAAP operating income decreased by 42% to $38.7 million, with an operating margin of 12.2% compared to 22.1% in the prior year[8] - Adjusted operating income increased by 11% to $110.3 million, compared to $99.6 million in the same quarter last year[9] - Adjusted operating margin percentage for the quarter was 34.9%, up from 33.0% in the same quarter of 2024, indicating stronger profitability[32] - Non-GAAP adjusted net earnings for the quarter were $88,318,000, compared to $76,425,000 in the same quarter of 2024, representing a 15.5% increase[35] - Net earnings for the nine months ended March 31, 2025, were $91,078, down from $127,517 in the prior year, a decrease of 28.5%[43] - Adjusted EBITDA for the nine months was $314,054, up from $299,916, indicating a growth of 4.7%[43] Cash Flow and Investments - Net cash provided by operating activities for the nine months was $189,355, compared to $223,485 in the previous year, a decline of 15.2%[45] - Cash and cash equivalents at the end of the period were $140,670, slightly up from $139,915 a year ago[45] - The company reported a net cash used in investing activities of $(35,589), compared to $(194,222) in the previous year, showing a significant reduction in cash outflow[45] - The company made an investment of $15,000 in Spear Bio during the nine months[45] Balance Sheet and Equity - Total assets as of March 31, 2025, were $2,644,259,000, a decrease from $2,703,867,000 as of June 30, 2024[28] - Stockholders' equity decreased to $2,018,025,000 from $2,068,850,000, reflecting changes in retained earnings and other comprehensive income[28] - Long-term debt obligations increased to $330,000,000 from $319,000,000, indicating a slight rise in leverage[28] Future Outlook - The company remains well positioned geographically and by end market, supported by an experienced leadership team[4] - Future outlook includes navigating a dynamic macroenvironment and focusing on profitability initiatives[4] Other Financial Metrics - Gross margin percentage under GAAP for the quarter was 67.9%, compared to 67.4% in the prior year, reflecting improved operational efficiency[29] - The company recognized certain litigation charges amounting to $38,927 in the current quarter[42] - Stock-based compensation expense increased to $36,283 for the nine months, compared to $30,979 in the prior year, a rise of 17.4%[45] - Protein Sciences segment operating income increased to $103,910, up from $94,829 in the same quarter last year, representing a growth of 11.5%[42] - Adjusted operating income for the quarter was $110,320, compared to $99,587 in Q3 2024, reflecting a year-over-year increase of 10.4%[42]

Core Insights - Bio-Techne Corporation reported strong financial results for the third quarter ending March 31, 2025, with a net sales increase of 4% to $316.2 million and organic revenue growth of 6% compared to the prior year [6][8][23] - The company achieved an adjusted operating margin of 34.9%, up 190 basis points from the previous year, driven by profitability initiatives and volume leverage [4][9][30] - GAAP earnings per share (EPS) decreased to $0.14 from $0.31 in the same quarter last year, while adjusted EPS increased to $0.56 from $0.48 [7][9][28] Financial Performance - Net sales for the third quarter were $316.2 million, a 4% increase year-over-year, with organic revenue growth of 6% [6][8] - GAAP operating income decreased by 42% to $38.7 million, resulting in a GAAP operating margin of 12.2%, down from 22.1% in the prior year [7][30] - Adjusted operating income rose 11% to $110.3 million, with an adjusted operating margin of 34.9% compared to 33.0% in the prior year [9][30] Segment Performance - The Protein Sciences segment reported net sales of $227.7 million, a 6% increase from $214.6 million in the same quarter last year, with an organic revenue growth of 7% [11][30] - The Diagnostics and Spatial Biology segment achieved net sales of $89.2 million, a 2% increase from $87.5 million, with organic revenue growth of 2% [12][30] Non-GAAP Financial Measures - Adjusted EPS for the third quarter was $0.56, an increase from $0.48 in the same quarter last year [9][28] - Adjusted EBITDA for the quarter was $122.2 million, compared to $109.3 million in the prior year [31] - The non-GAAP adjusted tax rate was reported at 21.5%, consistent with the previous year [28][29]

Core Points - Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ended March 31, 2025, payable on May 30, 2025, to shareholders of record on May 19, 2025 [1] - The company has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock, starting May 8, 2025, replacing the previous program [2] - Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people globally [3] Dividend Information - The quarterly dividend is set at $0.08 per share for the quarter ended March 31, 2025 [1] - The dividend payment date is May 30, 2025, with a record date of May 19, 2025 [1] Share Repurchase Program - The new share repurchase program allows for the repurchase of up to $500 million of common stock [2] - The program's execution will depend on share price, economic conditions, and regulatory requirements [2] - The company retains the right to suspend, amend, or discontinue the program at any time [2] Company Overview - Bio-Techne is a global life sciences company providing tools and bioactive reagents for research and clinical diagnostics [3] - The company's products support scientific investigations into biological processes and disease progression, aiding drug discovery and clinical testing [3] - Bio-Techne has a diverse portfolio with thousands of products [3]

Summary⚈ Congresswoman April McClain Delaney bought Bio-Techne stock twice in April 2025.⚈ The stock has dropped nearly 30% year-to-date and remains unprofitable post-purchase.⚈ Delaney’s committee roles suggest potential informational advantages in biotech-related decisions.Finbold’s congressional trading radar has recently picked up a suspicious stock bet made by Maryland congresswoman April McClain Delaney involving a low-profile biotech stock. The representative purchased Bio-Techne Corp stock (NASDAQ: ...

Core Viewpoint - Cyber Enviro-Tech, Inc. is conducting critical testing of its advanced water purification technology for the oil and gas industry, which could lead to contracts valued at over $100 million annually if successful [1][4]. Group 1: Technology and Testing - The testing aims to purify produced water, a byproduct of oil and gas extraction, which typically contains high concentrations of salts, hydrocarbons, heavy metals, and other contaminants [2]. - The goal is to reduce Total Dissolved Solids levels from 300,000 parts per million to the EPA standard of 500 ppm [2]. - Successful verification by independent laboratory results would enable the recycling of produced water for reuse in the oil industry, providing a more environmentally responsible and cost-effective alternative to deep underground injection [3]. Group 2: Environmental Impact - The ability to purify produced water to EPA standards has significant implications for water conservation and environmental sustainability [4]. - In Texas alone, over 10 billion barrels of produced water are injected underground each year, which removes vast quantities from the usable water supply [3]. Group 3: Company Overview - Cyber Enviro-Tech, Inc. operates internationally in eco-conscious oil sludge, water, and soil remediation projects, utilizing proprietary bioremedial materials and technologies [5]. - The company integrates Fourth Industrial Revolution technologies, including machine learning, artificial intelligence, cloud computing, and SCADA systems, alongside non-chemical bioremediation techniques [5].

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

Core Insights - March Biosciences has been awarded a $200,000 G-Rex® Grant to advance the manufacturing of its lead asset, MB-105, a novel CAR-T cell therapy targeting CD5 for T-cell lymphomas [1][5]. Company Developments - The grant will support the development of a scalable cGMP process using the G-Rex bioreactor, aimed at reducing complexity, time, and costs in manufacturing autologous CAR-T products [2][4]. - March Biosciences is focused on overcoming scalability and efficiency barriers in the manufacturing of MB-105, with the support of Wilson Wolf Manufacturing [3][5]. - The G-Rex Grant will facilitate the establishment of a fully integrated CAR-T cell manufacturing process, enhancing the production capabilities for MB-105 and other CAR-T products in development [4][6]. Industry Context - The G-Rex Grant Program, which has awarded nearly 200 grants, aims to advance cell and gene-modified cell therapy (CGT) development and manufacturing, with individual grants worth up to $300,000 [6][8]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, indicating its significant role in the industry [8]. - March Biosciences' MB-105 has received U.S. FDA orphan drug designation for treating relapsed/refractory CD5-positive T-cell lymphoma, highlighting its potential in addressing unmet medical needs [5][14].